MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapies aim to beat High-Risk blood cancers
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults took part…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
Experimental drug TAK-243 takes on tough blood cancers
Disease control TerminatedThis early-stage trial tests a new drug called TAK-243 in about 42 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or stopped responding to standard therapy. The main goals are to find the best dose and check for side effects. TAK-243 works by blockin…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New drug combo shows promise for blood cancers, but cure not yet in sight
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works at controlling the disease. About 135 adults with these bloo…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 11:24 UTC
-
New combo pill aims to beat back rare bone marrow cancers
Disease control OngoingThis phase 2 trial tests whether adding venetoclax to the drug ASTX727 works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will receive either the combination or ASTX727 alon…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:46 UTC